Nektar gains; jury finds Lilly breached contract in drug partnership dispute
NKTR•A U.S. jury found Eli Lilly breached its contractual obligations to Nektar Therapeutics in their former drug partnership and awarded Nektar $90 million, plus interest to be determined by a judge. The verdict remains subject to post-trial proceedings and possible appeal.
1. Jury awards damages
A U.S. jury found Eli Lilly breached its contractual obligations to Nektar Therapeutics in their former collaboration on rezpegaldesleukin, a regulatory filing showed. The jury awarded Nektar $90 million in damages, plus interest to be determined later by the judge; the verdict remains subject to post-trial proceedings and possible appeal.
2. Drug partnership ended
Rezpegaldesleukin is an experimental drug Nektar is developing for inflammatory skin disorders and its lead drug program. Lilly was previously a development partner before ending the collaboration in 2023.
